Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

Next Previous
Trial Profile

A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VCN 01 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VIRAGE
  • Sponsors VCN Biosciences

Most Recent Events

  • 27 May 2025 According to the Theriva Biologics media release, the company senior management will participate in an off-site meeting on Monday June 2nd, 2025 to review the recently reported topline results of this study with investigators and garner additional insights.
  • 15 May 2025 Primary endpoint (Incidence of Adverse Events after VCN-01 IV administration) has been met, according to results presented in the Theriva Biologics Media Release.
  • 15 May 2025 Primary endpoint(Overall Survival [ Time Frame: From randomization until death for any cause up to 3 years ]) has been met, according to results presented in the Theriva Biologics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top